Overview

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose-related safety, tolerability, pharmacokinetics (PK) and pharmacological effects (PD) of CORT125329 after single and multiple ascending oral doses of CORT125329 lipid capsule formulations in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Corcept Therapeutics
Treatments:
Prednisone